In: Type 2 Diabetes - From Diagnosis to Effective Management [Working Title]
Because our program is a direct-pay service, it is generally not eligible for reimbursement through insurance plans like GEHA
However, compounded medications carry additional risks due to their lack of FDA approval
These competitors are advancing treatments that could offer better control of blood glucose levels, reduced side effects, fewer injections, weight loss benefits, and improved cardiovascular outcomes
A: Current trial data suggests orforglipron may produce around 9% to 10% body weight reduction in some populations, while injectable semaglutide has shown higher average weight-loss outcomes in longer trials
Want a simple, daily protein habit without having to make a smoothie (you prefer something lighter and easy to sip)